“…The mAb HC 10, which recognizes a determinant expressed on all h2-microglobulin-free HLA-B HCs and on h2-microglobulin-free HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, and HLA-A33 HC (15,16); the anti-h2-microglobulin-specific mAb L368 (17) and the mAb TP25.99, which recognizes a conformational determinant expressed on all h2-microglobulin-associated HLA-ABC HC and a linear determinant expressed on all h2-microglobulin-free HLA-B HC except HLA-B73 and on h2-microglobulin-free HLA-A1, HLA-A3, HLA-A9, HLA-A11, and HLA-A30 HC were developed and characterized as described (18). The MB-1-mAb SY-1, the LMP7-specific mAb SY-3, the LMP10-specific mAb TO-7, the TAP2-specific mAb NOB-2, the calnexin-specific mAb TO-5, the calreticulinspecific mAb TO-11, the ERp57-specific mAb TO-2, and the tapasin-specific mAb TO-3 were developed and characterized as described elsewhere (19,20).…”